DE60124927D1 - Verfahren und zusammensetzungen zur inhibition der angiogenese - Google Patents

Verfahren und zusammensetzungen zur inhibition der angiogenese

Info

Publication number
DE60124927D1
DE60124927D1 DE60124927T DE60124927T DE60124927D1 DE 60124927 D1 DE60124927 D1 DE 60124927D1 DE 60124927 T DE60124927 T DE 60124927T DE 60124927 T DE60124927 T DE 60124927T DE 60124927 D1 DE60124927 D1 DE 60124927D1
Authority
DE
Germany
Prior art keywords
compounds
angiogenesis
methods
inhibiting
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60124927T
Other languages
English (en)
Other versions
DE60124927T2 (de
Inventor
C Sharma
P Tuszynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philadelphia Health and Education Corp
Original Assignee
Philadelphia Health and Education Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Health and Education Corp filed Critical Philadelphia Health and Education Corp
Publication of DE60124927D1 publication Critical patent/DE60124927D1/de
Application granted granted Critical
Publication of DE60124927T2 publication Critical patent/DE60124927T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60124927T 2000-09-01 2001-09-04 Verfahren und zusammensetzungen zur inhibition der angiogenese Expired - Fee Related DE60124927T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22966700P 2000-09-01 2000-09-01
US229667P 2000-09-01
US27720401P 2001-03-20 2001-03-20
US277204P 2001-03-20
PCT/US2001/027310 WO2002017857A2 (en) 2000-09-01 2001-09-04 Methods and compositions for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
DE60124927D1 true DE60124927D1 (de) 2007-01-11
DE60124927T2 DE60124927T2 (de) 2007-09-20

Family

ID=26923501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124927T Expired - Fee Related DE60124927T2 (de) 2000-09-01 2001-09-04 Verfahren und zusammensetzungen zur inhibition der angiogenese

Country Status (9)

Country Link
EP (1) EP1313504B1 (de)
JP (1) JP2004507482A (de)
AT (1) ATE346607T1 (de)
AU (1) AU2001288648A1 (de)
CA (1) CA2421503A1 (de)
DE (1) DE60124927T2 (de)
DK (1) DK1313504T3 (de)
ES (1) ES2272537T3 (de)
WO (1) WO2002017857A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60134885D1 (de) 2000-11-28 2008-08-28 David M Waisman Antiangiogene polypeptide
AU2003297181A1 (en) 2002-12-13 2004-07-09 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
WO2005027965A1 (en) * 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
DE102004046540A1 (de) * 2004-09-21 2006-04-06 Eberhard-Karls-Universität Tübingen Universitätsklinikum Annexin-Modulation und Infektionsresistenz
US20060111423A1 (en) * 2004-10-26 2006-05-25 Zeligs Michael A Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
WO2012048190A1 (en) * 2010-10-08 2012-04-12 Regents Of The University Of Minnesota Annexin ii compositions and methods
ES2928331T3 (es) * 2013-11-13 2022-11-17 Univ Minnesota Composiciones de variantes de anexina II y métodos
EP3045470A1 (de) 2015-01-15 2016-07-20 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Modulatoren der Funktion der Kerndomäne von Annexinen und Verwendungen davon in der Autoimmun- und/oder Krebstherapie
DK3468621T3 (da) 2016-06-10 2022-12-05 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Kernedomæne af annexiner og anvendelser deraf i antigenindgivelse og vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051364A (en) * 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
CA2322843A1 (en) * 1998-03-27 1999-09-30 The Board Of Trustees Of The Leland Stanford, Jr. University Hypoxia-inducible human genes, proteins, and uses thereof
DK1107989T3 (da) * 1998-08-25 2010-05-25 Merck Patent Gmbh Ekspression og eksport af angiostatin og endostatin som immunfusiner

Also Published As

Publication number Publication date
EP1313504A4 (de) 2004-06-30
ES2272537T3 (es) 2007-05-01
DE60124927T2 (de) 2007-09-20
EP1313504A2 (de) 2003-05-28
JP2004507482A (ja) 2004-03-11
ATE346607T1 (de) 2006-12-15
EP1313504B1 (de) 2006-11-29
DK1313504T3 (da) 2007-02-26
WO2002017857A2 (en) 2002-03-07
AU2001288648A1 (en) 2002-03-13
WO2002017857A3 (en) 2002-06-13
CA2421503A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
BG101841A (en) Cellular adhesion inhibitors
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
MY134783A (en) Rho-kinase inhibitors
MY142915A (en) Rho-kinase inhibitors
DK0721449T3 (da) Inhibitorer af beta-amyloidproteinproduktion
DE60014873D1 (de) Synergistische zusammensetzungen zur krebsbehandlung
BR0008922A (pt) Compostos úteis como agentes antiinflamatórios
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
NO996578L (no) Urokinase-inhibitorer
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
WO2003106381A3 (en) ADAM 10 HUMAN INHIBITORS
ATE266031T1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
DE60022867D1 (de) 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DE69819515D1 (de) Hydroxy-prostaglandinderivaten zur behandlung der erektilen dysfunktion
DE60124927D1 (de) Verfahren und zusammensetzungen zur inhibition der angiogenese
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE60214388D1 (de) Verbindungen, bei denen es sich um wirksame inhibitoren des na+/ca2+ austauschmechanismus handelt und die sich zur behandlung von arrhythmien eignen
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE425756T1 (de) Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee